Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction: An embedded cohort evaluation of the FOCUS-CCTRN trial

Doris A. Taylor, Emerson C. Perin, James T. Willerson, Claudia Zierold, Micheline Resende, Marjorie Carlson, Belinda Nestor, Elizabeth Wise, Aaron Orozco, Carl J. Pepine, Timothy D. Henry, Stephen G. Ellis, David X M Zhao, Jay H. Traverse, John P. Cooke, Robert C. Schutt, Aruni Bhatnagar, Maria B. Grant, Dejian Lai, Brian H. JohnstoneShelly L. Sayre, Lem Moyé, Ray F. Ebert, Roberto Bolli, Robert D. Simari, Christopher R. Cogle

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In the current study, we sought to identify bone marrow-derived mononuclear cell (BM-MNC) subpopulations associated with a combined improvement in left ventricular ejection fraction (LVEF), left ventricular endsystolic volume (LVESV), and maximal oxygen consumption (VO2 max) in patients with chronic ischemic cardiomyopathy 6 months after receiving transendocardial injections of autologous BM-MNCs or placebo. For this prospectively planned analysis, we conducted an embedded cohort study comprising 78 patients from the FOCUS-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Baseline BM-MNC immunophenotypes and progenitor cell activity were determined by flow cytometry and colony-forming assays, respectively. Previously stable patients who demonstrated improvement in LVEF, LVESV, and VO2 max during the 6-month course of the FOCUS-CCTRN study (group 1, n = 17) were compared to those who showed no change or worsened in one to three of these endpoints (group 2, n = 61) and to a subset of patients from group 2 who declined in all three functional endpoints (group 2A, n = 11). Group 1 had higher frequencies of B-cell and CXCR4+ BM-MNC subpopulations at study baseline than group 2 or 2A. Furthermore, patients in group 1 had fewer endothelial colony-forming cells and monocytes/macrophages in their bone marrow than those in group 2A. To our knowledge, this is the first study to show that in patients with ischemic cardiomyopathy, certain bone marrow-derived cell subsets are associated with improvement in LVEF, LVESV, and VO2 max at 6 months. These results suggest that the presence of both progenitor and immune cell populations in the bone marrow may influence the natural history of chronic ischemic cardiomyopathy—even in stable patients. Thus, it may be important to consider the bone marrow composition and associated regenerative capacity of patients when assigning them to treatment groups and evaluating the results of cell therapy trials.

Original languageEnglish (US)
Pages (from-to)1675-1687
Number of pages13
JournalCell Transplantation
Volume25
Issue number9
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Left Ventricular Dysfunction
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Bone
Cells
Bone Marrow
Research
Stroke Volume
Cardiomyopathies
Stem Cells
Flow cytometry
Macrophages
Functional groups
Natural History
Assays
Oxygen Consumption
Monocytes
Flow Cytometry
B-Lymphocytes
Cohort Studies

Keywords

  • Bone marrow
  • Cell therapy
  • Heart failure
  • Ischemic cardiomyopathy
  • Stem cells

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction : An embedded cohort evaluation of the FOCUS-CCTRN trial. / Taylor, Doris A.; Perin, Emerson C.; Willerson, James T.; Zierold, Claudia; Resende, Micheline; Carlson, Marjorie; Nestor, Belinda; Wise, Elizabeth; Orozco, Aaron; Pepine, Carl J.; Henry, Timothy D.; Ellis, Stephen G.; Zhao, David X M; Traverse, Jay H.; Cooke, John P.; Schutt, Robert C.; Bhatnagar, Aruni; Grant, Maria B.; Lai, Dejian; Johnstone, Brian H.; Sayre, Shelly L.; Moyé, Lem; Ebert, Ray F.; Bolli, Roberto; Simari, Robert D.; Cogle, Christopher R.

In: Cell Transplantation, Vol. 25, No. 9, 2016, p. 1675-1687.

Research output: Contribution to journalArticle

Taylor, DA, Perin, EC, Willerson, JT, Zierold, C, Resende, M, Carlson, M, Nestor, B, Wise, E, Orozco, A, Pepine, CJ, Henry, TD, Ellis, SG, Zhao, DXM, Traverse, JH, Cooke, JP, Schutt, RC, Bhatnagar, A, Grant, MB, Lai, D, Johnstone, BH, Sayre, SL, Moyé, L, Ebert, RF, Bolli, R, Simari, RD & Cogle, CR 2016, 'Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction: An embedded cohort evaluation of the FOCUS-CCTRN trial', Cell Transplantation, vol. 25, no. 9, pp. 1675-1687. https://doi.org/10.3727/096368915X689901
Taylor, Doris A. ; Perin, Emerson C. ; Willerson, James T. ; Zierold, Claudia ; Resende, Micheline ; Carlson, Marjorie ; Nestor, Belinda ; Wise, Elizabeth ; Orozco, Aaron ; Pepine, Carl J. ; Henry, Timothy D. ; Ellis, Stephen G. ; Zhao, David X M ; Traverse, Jay H. ; Cooke, John P. ; Schutt, Robert C. ; Bhatnagar, Aruni ; Grant, Maria B. ; Lai, Dejian ; Johnstone, Brian H. ; Sayre, Shelly L. ; Moyé, Lem ; Ebert, Ray F. ; Bolli, Roberto ; Simari, Robert D. ; Cogle, Christopher R. / Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction : An embedded cohort evaluation of the FOCUS-CCTRN trial. In: Cell Transplantation. 2016 ; Vol. 25, No. 9. pp. 1675-1687.
@article{733d19bba0934a80b1021c5057c0ed15,
title = "Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction: An embedded cohort evaluation of the FOCUS-CCTRN trial",
abstract = "In the current study, we sought to identify bone marrow-derived mononuclear cell (BM-MNC) subpopulations associated with a combined improvement in left ventricular ejection fraction (LVEF), left ventricular endsystolic volume (LVESV), and maximal oxygen consumption (VO2 max) in patients with chronic ischemic cardiomyopathy 6 months after receiving transendocardial injections of autologous BM-MNCs or placebo. For this prospectively planned analysis, we conducted an embedded cohort study comprising 78 patients from the FOCUS-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Baseline BM-MNC immunophenotypes and progenitor cell activity were determined by flow cytometry and colony-forming assays, respectively. Previously stable patients who demonstrated improvement in LVEF, LVESV, and VO2 max during the 6-month course of the FOCUS-CCTRN study (group 1, n = 17) were compared to those who showed no change or worsened in one to three of these endpoints (group 2, n = 61) and to a subset of patients from group 2 who declined in all three functional endpoints (group 2A, n = 11). Group 1 had higher frequencies of B-cell and CXCR4+ BM-MNC subpopulations at study baseline than group 2 or 2A. Furthermore, patients in group 1 had fewer endothelial colony-forming cells and monocytes/macrophages in their bone marrow than those in group 2A. To our knowledge, this is the first study to show that in patients with ischemic cardiomyopathy, certain bone marrow-derived cell subsets are associated with improvement in LVEF, LVESV, and VO2 max at 6 months. These results suggest that the presence of both progenitor and immune cell populations in the bone marrow may influence the natural history of chronic ischemic cardiomyopathy—even in stable patients. Thus, it may be important to consider the bone marrow composition and associated regenerative capacity of patients when assigning them to treatment groups and evaluating the results of cell therapy trials.",
keywords = "Bone marrow, Cell therapy, Heart failure, Ischemic cardiomyopathy, Stem cells",
author = "Taylor, {Doris A.} and Perin, {Emerson C.} and Willerson, {James T.} and Claudia Zierold and Micheline Resende and Marjorie Carlson and Belinda Nestor and Elizabeth Wise and Aaron Orozco and Pepine, {Carl J.} and Henry, {Timothy D.} and Ellis, {Stephen G.} and Zhao, {David X M} and Traverse, {Jay H.} and Cooke, {John P.} and Schutt, {Robert C.} and Aruni Bhatnagar and Grant, {Maria B.} and Dejian Lai and Johnstone, {Brian H.} and Sayre, {Shelly L.} and Lem Moy{\'e} and Ebert, {Ray F.} and Roberto Bolli and Simari, {Robert D.} and Cogle, {Christopher R.}",
year = "2016",
doi = "10.3727/096368915X689901",
language = "English (US)",
volume = "25",
pages = "1675--1687",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "9",

}

TY - JOUR

T1 - Identification of bone marrow cell subpopulations associated with improved functional outcomes in patients with chronic left ventricular dysfunction

T2 - An embedded cohort evaluation of the FOCUS-CCTRN trial

AU - Taylor, Doris A.

AU - Perin, Emerson C.

AU - Willerson, James T.

AU - Zierold, Claudia

AU - Resende, Micheline

AU - Carlson, Marjorie

AU - Nestor, Belinda

AU - Wise, Elizabeth

AU - Orozco, Aaron

AU - Pepine, Carl J.

AU - Henry, Timothy D.

AU - Ellis, Stephen G.

AU - Zhao, David X M

AU - Traverse, Jay H.

AU - Cooke, John P.

AU - Schutt, Robert C.

AU - Bhatnagar, Aruni

AU - Grant, Maria B.

AU - Lai, Dejian

AU - Johnstone, Brian H.

AU - Sayre, Shelly L.

AU - Moyé, Lem

AU - Ebert, Ray F.

AU - Bolli, Roberto

AU - Simari, Robert D.

AU - Cogle, Christopher R.

PY - 2016

Y1 - 2016

N2 - In the current study, we sought to identify bone marrow-derived mononuclear cell (BM-MNC) subpopulations associated with a combined improvement in left ventricular ejection fraction (LVEF), left ventricular endsystolic volume (LVESV), and maximal oxygen consumption (VO2 max) in patients with chronic ischemic cardiomyopathy 6 months after receiving transendocardial injections of autologous BM-MNCs or placebo. For this prospectively planned analysis, we conducted an embedded cohort study comprising 78 patients from the FOCUS-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Baseline BM-MNC immunophenotypes and progenitor cell activity were determined by flow cytometry and colony-forming assays, respectively. Previously stable patients who demonstrated improvement in LVEF, LVESV, and VO2 max during the 6-month course of the FOCUS-CCTRN study (group 1, n = 17) were compared to those who showed no change or worsened in one to three of these endpoints (group 2, n = 61) and to a subset of patients from group 2 who declined in all three functional endpoints (group 2A, n = 11). Group 1 had higher frequencies of B-cell and CXCR4+ BM-MNC subpopulations at study baseline than group 2 or 2A. Furthermore, patients in group 1 had fewer endothelial colony-forming cells and monocytes/macrophages in their bone marrow than those in group 2A. To our knowledge, this is the first study to show that in patients with ischemic cardiomyopathy, certain bone marrow-derived cell subsets are associated with improvement in LVEF, LVESV, and VO2 max at 6 months. These results suggest that the presence of both progenitor and immune cell populations in the bone marrow may influence the natural history of chronic ischemic cardiomyopathy—even in stable patients. Thus, it may be important to consider the bone marrow composition and associated regenerative capacity of patients when assigning them to treatment groups and evaluating the results of cell therapy trials.

AB - In the current study, we sought to identify bone marrow-derived mononuclear cell (BM-MNC) subpopulations associated with a combined improvement in left ventricular ejection fraction (LVEF), left ventricular endsystolic volume (LVESV), and maximal oxygen consumption (VO2 max) in patients with chronic ischemic cardiomyopathy 6 months after receiving transendocardial injections of autologous BM-MNCs or placebo. For this prospectively planned analysis, we conducted an embedded cohort study comprising 78 patients from the FOCUS-Cardiovascular Cell Therapy Research Network (CCTRN) trial. Baseline BM-MNC immunophenotypes and progenitor cell activity were determined by flow cytometry and colony-forming assays, respectively. Previously stable patients who demonstrated improvement in LVEF, LVESV, and VO2 max during the 6-month course of the FOCUS-CCTRN study (group 1, n = 17) were compared to those who showed no change or worsened in one to three of these endpoints (group 2, n = 61) and to a subset of patients from group 2 who declined in all three functional endpoints (group 2A, n = 11). Group 1 had higher frequencies of B-cell and CXCR4+ BM-MNC subpopulations at study baseline than group 2 or 2A. Furthermore, patients in group 1 had fewer endothelial colony-forming cells and monocytes/macrophages in their bone marrow than those in group 2A. To our knowledge, this is the first study to show that in patients with ischemic cardiomyopathy, certain bone marrow-derived cell subsets are associated with improvement in LVEF, LVESV, and VO2 max at 6 months. These results suggest that the presence of both progenitor and immune cell populations in the bone marrow may influence the natural history of chronic ischemic cardiomyopathy—even in stable patients. Thus, it may be important to consider the bone marrow composition and associated regenerative capacity of patients when assigning them to treatment groups and evaluating the results of cell therapy trials.

KW - Bone marrow

KW - Cell therapy

KW - Heart failure

KW - Ischemic cardiomyopathy

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84984596856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984596856&partnerID=8YFLogxK

U2 - 10.3727/096368915X689901

DO - 10.3727/096368915X689901

M3 - Article

AN - SCOPUS:84984596856

VL - 25

SP - 1675

EP - 1687

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 9

ER -